Increased risk for atypical fractures associated with bisphosphonate use. (Q38407671)

2 September 2017

0 references

1 reference

title

Increased risk for atypical fractures associated with bisphosphonate use. (English)

1 reference

2 September 2017

Soyon Lee

1

1 reference

2 September 2017

Raynold V Yin

2

1 reference

2 September 2017

Hemant Hirpara

3

1 reference

2 September 2017

Nancy C Lee

4

1 reference

2 September 2017

Adrian Lee

5

1 reference

2 September 2017

Samantha Llanos

6

1 reference

2 September 2017

Olivia J Phung

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

5 April 2015

1 reference

2 September 2017

1 reference

2 September 2017

32

1 reference

2 September 2017

3

1 reference

2 September 2017

276-281

1 reference

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

2 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Atypical fractures as a potential complication of long-term bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Barriers to influenza immunization in a low-income urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMU088

21 January 2018

Identifiers

DOI

10.1093/FAMPRA/CMU088

1 reference

2 September 2017

1 reference